Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis-Reference-Cited by-同舟云学术

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

Published:2020-02 Issue: Volume:140 Page:99-106
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Giaj Levra Matteo,Cotté François-Emery,Corre Romain^ORCID,Calvet Christophe,Gaudin Anne-Françoise,Penrod John R.,Grumberg Valentine,Jouaneton Baptiste,Jolivel Ronan,Assié Jean-Baptiste,Chouaïd Christos^ORCID

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int. Immunopharmacol.,2018

2. Immune checkpoint blockade in Cancer therapy;Postow;J. Clin. Oncol.,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases;Vokes;Ann. Oncol.,2018

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma;Investigational New Drugs;2024-08-30

3. Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma;Clinical and Translational Oncology;2024-07-24

4. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy;Journal of Clinical Oncology;2024-07-10

5. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07